Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies
{{output}}
Background: Chimeric antigen receptor T-cell (CAR-T) cell therapy represents a significant advancement in cancer treatment, offering remarkable responses in certain hematologic malignancies. However, the risk of secondary primary... ...
